Multiple Myeloma

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

Multiple Myeloma Recent News

iTeos Posts New Preclinical Data For Anti-TIGIT Antibody At ASH 2021
ITeos Therapeutics Inc (NASDAQ: ITOS) 
Why Are Legend Biotech Shares Gaining Today?
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has 
Gracell Biotech Stock Jumps On Orphan Drug Tag For Multiple Myeloma CAR-T Cell Therapy
Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ) Darzalex for previously untreated patients with multiple myeloma.
Europe Approves Bristol Myers' BCMA-Targeted Multiple Myeloma Immunotherapy
Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma
C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
Sanofi Bets Over $1B For Eureka's Multiple Myeloma Candidate
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma
Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US
Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy
BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients
SpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma Patients
SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Janssen's teclistamab in patients with relapsed or refractory multiple myeloma. Nirogacestat is an investigational gamma-secretase inhibitor (GSI) developed by SpringWorks.
Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China
GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
GlaxoSmithKline plc (NYSE: GSK) announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults.
Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug